Unveiling the taxonomic diversity and unprecedented biosynthetic treasure of the phylum Myxococcota

2026 · doi:10.64898/2026.02.12.705523
preprint OA: closed CC-BY-4.0
🔓 Open OA copy Full text JSON View at publisher
⚙ AI-generated deep summary by claude@2026-07, 2026-07-06 · read from full text ⓘ

The study analyzed natural-product biosynthetic potential in the bacterial phylum Myxococcota by presenting 154 new Myxococcota genomes and revising taxonomy, increasing described families from 11 to 28 and genera from 32 to 90. Genome comparisons with Actinomycetota indicated that Myxococcota have comparable biosynthetic diversity, and genome mining of 2,387 uncharacterized gene cluster families led to four validated compounds with novel chemistry, including myxolutamids and myxopentacins. The paper also reports lineage-conserved natural products, such as myxolutamid A and two new sorangicin derivatives, and states that precise taxonomic classification helps relate biosynthetic potential to targeted drug discovery, with the main caveat being reliance on genome mining/validation rather than broader in vivo context. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Natural products remain vital sources of therapeutics, particularly anti-infectives, and members of the phylum Myxococcota constitute an especially rich reservoir for their discovery. Based on decades of microbiological efforts, we present 154 new Myxococcota genomes and propose a revised taxonomy expanding the number of described families from 11 to 28 and genera from 32 to 90. Comparison with an equivalent set from the prime source Actinomycetota shows that Myxococcota possess a comparable biosynthetic diversity, underscoring their promise for large-scale isolation and sequencing efforts. The vast untapped potential reflected in 2,387 uncharacterized gene cluster families is highlighted by genome mining efforts, yielding four validated compounds exhibiting novel chemistry, including myxolutamids and myxopentacins. We show that many Myxococcota-derived natural products, such as myxolutamid A and two new sorangicin derivatives, are conserved within taxonomic lineages. New described families thus bear high biosynthetic potential underpinning the importance of precise taxonomic classification guiding targeted drug discovery.
Full text 2,004 characters · extracted from oa-doi-fallback · click to expand
Unveiling the taxonomic diversity and unprecedented biosynthetic treasure of the phylum Myxococcota ABSTRACT Natural products remain vital sources of therapeutics, particularly anti-infectives, and members of the phylum Myxococcota constitute an especially rich reservoir for their discovery. Based on decades of microbiological efforts, we present 154 new Myxococcota genomes and propose a revised taxonomy expanding the number of described families from 11 to 28 and genera from 32 to 90. Comparison with an equivalent set from the prime source Actinomycetota shows that Myxococcota possess a comparable biosynthetic diversity, underscoring their promise for large-scale isolation and sequencing efforts. The vast untapped potential reflected in 2,387 uncharacterized gene cluster families is highlighted by genome mining efforts, yielding four validated compounds exhibiting novel chemistry, including myxolutamids and myxopentacins. We show that many Myxococcota-derived natural products, such as myxolutamid A and two new sorangicin derivatives, are conserved within taxonomic lineages. New described families thus bear high biosynthetic potential underpinning the importance of precise taxonomic classification guiding targeted drug discovery. Competing Interest Statement Rolf Mueller, Peter Sullivan, Ronald Garcia and Olga Kalinina are founders of Myxotech GmbH. Funder Information Declared Subject Area - Biochemistry (17690) - Bioengineering (13892) - Bioinformatics (41936) - Biophysics (21451) - Cancer Biology (18588) - Cell Biology (25499) - Clinical Trials (138) - Developmental Biology (13378) - Ecology (19899) - Epidemiology (2067) - Evolutionary Biology (24320) - Genetics (15609) - Genomics (22506) - Immunology (17736) - Microbiology (40394) - Molecular Biology (17181) - Neuroscience (88603) - Paleontology (666) - Pathology (2832) - Pharmacology and Toxicology (4824) - Physiology (7641) - Plant Biology (15152) - Synthetic Biology (4294) - Systems Biology (9825) - Zoology (2271)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-27T02:00:06.600101+00:00
License: CC-BY-4.0